Racura Oncology (RAC) Q1 2026 TU earnings summary

Executive summary

• Filed breakthrough IP for bisantrene, discovering three photoisomers with distinct anticancer activities and rapid interconversion under visible light.

• Advanced Phase 1 clinical trial of RC220 (RAC-010), with two patients safely treated as single agent and in combination with doxorubicin.

• Received regulatory and ethics approvals in Hong Kong and South Korea, enabling multi-site international trial expansion.

• Published positive Phase 2 results for bisantrene in combination therapy for relapsed/refractory AML, exceeding efficacy goals.

• Discovered (E,E)-bisantrene's primary anticancer mechanism is G-quadruplex DNA/RNA binding, impacting key cancer genes.

Financial highlights

• Cash and cash equivalents at quarter end: $11.27 million.

• 78% of spending ($2.3m) directed to R&D and drug manufacturing.

• Early option conversions raised $0.6m during the quarter and $3.08m post quarter, totaling $3.6m additional funding.

• Net cash used in operating activities: $(3.02)m for the quarter.

• Estimated 3.73 quarters of funding available at current burn rate.

Outlook and guidance

• Current cash position and additional funding expected to support all announced activities through CY2026.

• Increased patient recruitment anticipated in Q2 FY2026 with activation of five new clinical sites.

• Advancement of RC110 formulation into pivotal Phase 3 trial planned, pending partner support.